Flow cytometry has shown that inhibiting FSP1 significantly increases the presence of macrophages, dendritic cells, and T cells in HCC tumors, while also markedly reducing tumor size without negatively impacting body weight in animal models. This evidence concerns the gene AIFM2 and hepatocellular carcinoma.